Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
News | 22 May 2012
AUSTIN, Texas, May 22, 2012 /PRNewswire via COMTEX/ -- Prodigy Generics, a division of Prodigy Health Supplier Corporation (PHS), has launched injectable irinotecan. Irinotecan is the generic equivalent of the branded drug Camptosar by Pfizer.
Click on the link to read the full article at MarketWatch (press release)
(This link will open in a new window)
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
